India’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...

Smallcap and midcap stocks surged on Wednesday, outperforming broader market indices with gains of around 1% each. This rally was fueled by...

Indian markets are set for a dynamic start today. Investors will closely watch the Q4 results from banking giants HDFC Bank and ICICI Bank....

Lupin shares rose on Friday after the pharma major reported a robust 73% YoY surge in Q2 FY26 PAT to Rs 1,485 crore, driven by strong sales...

Lupin's shares are in focus following a robust Q1 performance, with net profit surging 52% to Rs 1,221 crore, fueled by strong US and India...

JM Financial has maintained its Buy rating on Crompton Greaves Consumer, emphasizing the company's entry into the solar rooftop segment and...

Advait Energy Transitions received letter of intent (LoI) from Gujarat Urja Vikas Nigam for setting up of a 50 MW out of 500 MW/1000 MWh st...

Now that Swaminathan is back, Lupin’s shareholders may expect improvement in the company’s performance.

The company had reported PAT of Rs 547 crore in the same quarter last financial year.

Mumbaibased pharma company Lupin has posted better-than-expected numbers after reporting dismal figures for four successive quarters.

Some midcap pharma companies though have come up with encouraging numbers, but overall this is a time to step back, says Shenoy.

Lupin’s move to acquire Gavis Pharmaceuticals for $880 million, approximately Rs 5600 crore, is seen as a long-term positive.

The proposal was cleared in the meeting of the Cabinet Committee on Economic Affairs (CCEA) headed by Prime Minister Narendra Modi.

When the company announced long-term strategic partnership with Merck Serono (MS), the biopharmaceutical division of Merck, the stock came ...

According to ET NOW, domestic formulations business is likely to grow by 20-23 per cent while the exports may see growth of 35 per cent. Hi...

Domestic drug maker Lupin on Friday announced that its US subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has received the final approval for...

Pharma company Lupin Ltd on Thursday said it will announce unaudited financial results for the quarter ending September 30, on October 19.